• S17:E3 – Morning Commute Podcast: The Rationale for More Potent FLT3 Inhibitors for Acute Myeloid Leukemia – Enter Quizatinib

  • Nov 15 2023
  • Length: 32 mins
  • Podcast
S17:E3 – Morning Commute Podcast: The Rationale for More Potent FLT3 Inhibitors for Acute Myeloid Leukemia – Enter Quizatinib By cover art

S17:E3 – Morning Commute Podcast: The Rationale for More Potent FLT3 Inhibitors for Acute Myeloid Leukemia – Enter Quizatinib

Listen for free

View show details

  • Summary

  • The treatment paradigm for the treatment of AML is changing. In this podcast, our faculty discuss quizartinib and the QuANTUM-First trial. 

    Visit www.morningcommutepodcast.com/aml3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
    Show more Show less
Show more Show less

What listeners say about S17:E3 – Morning Commute Podcast: The Rationale for More Potent FLT3 Inhibitors for Acute Myeloid Leukemia – Enter Quizatinib

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available